Endocrine Disorders for the USMLE, Step One

Total Page:16

File Type:pdf, Size:1020Kb

Endocrine Disorders for the USMLE, Step One Endocrine Disorders for the USMLE, Step One: Multiple Endocrine Neoplasia Type 1 (MEN-1 Syndrome) Howard J. Sachs, MD www.12DaysinMarch.com Endocrine Disorders for the USMLE, Step One: Multiple Endocrine Neoplasia Type 1 View MEN2 Syndromes BEFORE (MEN-1 Syndrome) this video Howard J. Sachs, MD www.12DaysinMarch.com MEN-1 Syndrome Pituitary Parathyroid Pancreas MEN-1 Syndrome Pituitary Parathyroid Pancreas 3-P’s MEN-1 Syndrome Pituitary Parathyroid Pancreas 3-P’s MEN-1 Syndrome Before proceeding, we need to change the name into something more memorable and informative. Once we move from MEN-1 and the 3-P’s, the rest is a breeze. Pituitary ParathyroidReally. Pancreas 3-P’s MEN-1 Syndrome Parathyroid Pancreas Pituitary ~100% ~60% ~20% MEN-1 Syndrome Parathyroid Pancreas Pituitary ~100% ~60% ~20% Multiple Adenomas Gastrinoma (ZE) Prolactinoma MEN-1 Syndrome Pituitary Pancreas Parathyroid ~20% ~60% ~100% Prolactinoma Gastrinoma (ZE) Ca+2 MEN-1 Syndrome Pituitary Pancreas Parathyroid ~20% ~60% ~100% Prolactinoma Gastrinoma (ZE) Ca+2 Pro-ZE-Ca Syndrome MEN 1: Pro-ZE-Ca Syndrome Pituitary Pancreas Parathyroid ~20% ~60% ~100% Prolactinoma Gastrinoma (ZE) Multiple Adenomas Mass Effect Multiple/Atypical Ca+2 Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome What are the take homes? Background: A. High penetrance B. Initial presention in majority of MEN C. Compared with sporadic: • PituitaryMultiple adenomas and earlyPancreas age Parathyroid ~20% Presentation: ~60% ~100% D. SameProlactinoma as any other patientGastrinoma with hyperPTH (ZE) Multiple Adenomas • Ca, PTH, PO4- • MassStones, Effect Constipation Multiple/Atypical Ca+2 Hormonal• X- Dysfunctionray: subperiosteal bone Ulcersresorption MEN 1: Pro-ZE-Ca Syndrome What are the take homes? Background: A. High penetrance B. Initial presention in majority of MEN C. Compared with sporadic: • PituitaryMultipleOn USMLE, adenomas any patient and early diagnosedPancreas age or presentingParathyroid with HyperPTH, you need be HyperVigilent for an ~20% MENPresentation Syndrome: (Type~60% 1 or 2a) ~100% D. SameProlactinoma as any other patientGastrinoma with hyperPTH (ZE) Multiple Adenomas • Ca, PTH, PO4- • MassStones, Effect Constipation Multiple/Atypical Ca+2 Hormonal• X- Dysfunctionray: subperiosteal bone Ulcersresorption MEN 1: Pro-ZE-Ca Syndrome What are the take homes? Background (Pancreatic Endocrine Tumors): A. Gastrinoma most common • May present in duodenal location B. Insulinoma, VIPoma, Glucagonoma • Hypoglycemia, WDHA, NME (bronze skin) C. Carcinoid (bronchial, thymus) Pancreas Pituitary Pancreas Presentation: ~60% ~20% ~60% D. Multiple or Atypical Ulcers Gastrinoma (ZE) • ProlactinomaDuodenal beyond D1 Gastrinoma (ZE) • Epigastric pain despite rx Multiple/Atypical E. DiarrheaMass Effect (inactivates lipase/acidicMultiple/Atypical lumen) Ulcers Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome What are the take homes? Diagnostics (Gastrinoma): 1. High gastric basal acid secretion Pancreas 2. GastrinPituitary Level Pancreas 3. Secretin Stimulation Test ~60% • Rise~20% in Gastrin Level ~60% Gastrinoma (ZE) Prolactinoma Gastrinoma (ZE) Multiple/Atypical Mass Effect Multiple/Atypical Ulcers Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome WhatBe on are the the lookout take homes? with any question that includes Gastrinoma , VIPoma, or Insulinoma. Diagnostics (Gastrinoma): If they include Ca+2, you have two components 1. High gastric basal acid secretionof MEN-1… Pancreas 2. GastrinPituitary Level Pancreas 3. Secretin Stimulation…they will Test most assuredly come after you on the ~60% • Rise~20% in Gastrin Level third component…~60% Gastrinoma (ZE) Prolactinoma Gastrinomathe Pituitary (ZE) Multiple/Atypical Mass Effect Multiple/Atypical Ulcers Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome What are the take homes? Background: 1. Adenomas of Anterior Pituitary follow same pattern as in non-MEN syndromes • Prolactin > Growth Hormone > Null Pituitary • HormonePancreas product versus MassParathyroid Effect ~20% ~60% ~100% Presentation: Prolactinoma 1. PituitaryGastrinoma mass (ZE) lesion: HA, visualMultiple field Adenomas cut 2. Prolactinoma: hypogonadotropic hypogonadism Mass Effect • Male:Multiple/Atypical libido/ ED Ca+2 Hormonal Dysfunction Ulcers • Female: menses, galactorrhea MEN 1: Pro-ZE-Ca Syndrome What are the take homes? Diagnostics: 1. Prolactin level 2. Men: LH, testosterone Pituitary 3. ImagingPancreas for mass effect orParathyroid PRL ~20% ~60% Note: ~100% Prolactinoma FrequencyGastrinoma (ZE) of pituitary Multiplelesion in Adenomas MEN-1 depends on how hard you look Mass Effect Multiple/Atypical(20% clinical, 60% by MRI screen) Ca+2 Hormonal Dysfunction Ulcers MEN 1: Pro-ZE-Ca Syndrome What are the take homes? Interestingly, I’ve mentioned you should Diagnosticsbe hypervigilant: looking for MEN1 in patients with1. hyperPTH Prolactin and/or level pancreatic masses or neuroendocrine tumors. 2. Men: LH, testosterone Pituitary On the other hand,3. questionsImagingPancreas involving for mass pituitary effect adenomas orParathyroid PRL are usually focused on the adenoma and secretions. ~20% ~60% Note: ~100% Prolactinoma FrequencyGastrinoma (ZE) of pituitary Multiplelesion in Adenomas MEN-1 depends on how hard you look Mass Effect Multiple/Atypical(20% clinical, 60% by MRI screen) Ca+2 Hormonal Dysfunction Ulcers MEN-1 Syndrome • Reviewed major components – Endocrinopathy (PTH, Pancreas, Pituitary) – Derm Manifestations Angiofibroma (90%) Collagenoma Lipoma MEN-1 Syndrome Lip/Tongue Neuromas seen in MEN2b • Reviewed major components – Endocrinopathy (PTH, Pancreas, Pituitary) – Derm Manifestations Angiofibroma (90%) Collagenoma Lipoma MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%; Ca+2) HyperPTH Marfanoid, Neuromas The most difficult part of an MEN Syndrome is knowing you are in one… Autosomal Dominant MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%; Ca+2) HyperPTH Marfanoid, Neuromas Autosomal Dominant MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%; Ca+2) HyperPTH Marfanoid, Neuromas Gain of function Loss of Suppressor MEN1 RET Mutation Mutation MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%; Ca+2) HyperPTH Marfanoid, Neuromas Gain of function Loss of Suppressor MEN1 RET Mutation Mutation MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%; Ca+2) HyperPTH Marfanoid, Neuromas Autosomal Dominant MEN-1 MEN-2 (Pro-ZE-Ca) 1. MTC (100%) 2. Pheochromocytoma (50%) 1. Pituitary (Prolactinoma) 2. Pancreas (Gastrinoma; ZE) 2a 2b 3. Parathyroid (100%; Ca+2) HyperPTH Marfanoid, Neuromas Endocrine Disorders for the USMLE, Step One: Multiple Endocrine Neoplasia Type 1 (Pro-ZE-Ca or MEN-1 Syndrome) Pro-ZE-Ca Howard J. Sachs, MD Email: [email protected] .
Recommended publications
  • Endo4 PRINT.Indb
    Contents 1 Tumours of the pituitary gland 11 Spindle epithelial tumour with thymus-like differentiation 123 WHO classifi cation of tumours of the pituitary 12 Intrathyroid thymic carcinoma 125 Introduction 13 Paraganglioma and mesenchymal / stromal tumours 127 Pituitary adenoma 14 Paraganglioma 127 Somatotroph adenoma 19 Peripheral nerve sheath tumours 128 Lactotroph adenoma 24 Benign vascular tumours 129 Thyrotroph adenoma 28 Angiosarcoma 129 Corticotroph adenoma 30 Smooth muscle tumours 132 Gonadotroph adenoma 34 Solitary fi brous tumour 133 Null cell adenoma 37 Haematolymphoid tumours 135 Plurihormonal and double adenomas 39 Langerhans cell histiocytosis 135 Pituitary carcinoma 41 Rosai–Dorfman disease 136 Pituitary blastoma 45 Follicular dendritic cell sarcoma 136 Craniopharyngioma 46 Primary thyroid lymphoma 137 Neuronal and paraneuronal tumours 48 Germ cell tumours 139 Gangliocytoma and mixed gangliocytoma–adenoma 48 Secondary tumours 142 Neurocytoma 49 Paraganglioma 50 3 Tumours of the parathyroid glands 145 Neuroblastoma 51 WHO classifi cation of tumours of the parathyroid glands 146 Tumours of the posterior pituitary 52 TNM staging of tumours of the parathyroid glands 146 Mesenchymal and stromal tumours 55 Parathyroid carcinoma 147 Meningioma 55 Parathyroid adenoma 153 Schwannoma 56 Secondary, mesenchymal and other tumours 159 Chordoma 57 Haemangiopericytoma / Solitary fi brous tumour 58 4 Tumours of the adrenal cortex 161 Haematolymphoid tumours 60 WHO classifi cation of tumours of the adrenal cortex 162 Germ cell tumours 61 TNM classifi
    [Show full text]
  • Endocrine Pathology (537-577)
    LABORATORY INVESTIGATION THE BASIC AND TRANSLATIONAL PATHOLOGY RESEARCH JOURNAL LI VOLUME 99 | SUPPLEMENT 1 | MARCH 2019 2019 ABSTRACTS ENDOCRINE PATHOLOGY (537-577) MARCH 16-21, 2019 PLATF OR M & 2 01 9 ABSTRACTS P OSTER PRESENTATI ONS EDUCATI ON C O M MITTEE Jason L. Hornick , C h air Ja mes R. Cook R h o n d a K. Y a nti s s, Chair, Abstract Revie w Board S ar a h M. Dr y and Assign ment Co m mittee Willi a m C. F a q ui n Laura W. La mps , Chair, C ME Subco m mittee C ar ol F. F ar v er St e v e n D. Billi n g s , Interactive Microscopy Subco m mittee Y uri F e d ori w Shree G. Shar ma , Infor matics Subco m mittee Meera R. Ha meed R aj a R. S e et h al a , Short Course Coordinator Mi c h ell e S. Hir s c h Il a n W ei nr e b , Subco m mittee for Unique Live Course Offerings Laksh mi Priya Kunju D a vi d B. K a mi n s k y ( Ex- Of ici o) A n n a M ari e M ulli g a n Aleodor ( Doru) Andea Ri s h P ai Zubair Baloch Vi nita Parkas h Olca Bast urk A nil P ar w a ni Gregory R. Bean , Pat h ol o gist-i n- Trai ni n g D e e p a P atil D a ni el J.
    [Show full text]
  • MDM2 Gene Polymorphisms May Be Associated with Tumor
    in vivo 31 : 357-363 (2017) doi:10.21873/invivo.11067 The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage SEDA TURGUT 1, MUZAFFER ILHAN 2, SAIME TURAN 3, OZCAN KARAMAN 2, ILHAN YAYLIM 3, OZLEM KUCUKHUSEYIN 3 and ERTUGRUL TASAN 2 Departments of 1Internal Medicine, and 2Endocrinology and Metabolism, Bezmialem Vakif University, Istanbul, Turkey; 3Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey → Abstract. Aim: Prolactinomas are thought to arise from genotype (TT+GG) of MDM2 SNP309T G was clonal expansion of a single mutated cell which is subjected significantly higher than in heterozygous genotype (TG) to growth stimuli of several permissive factors, although the carriers (odds ratio(OR)=0.18, 95% confidence pathogenetic mechanisms underlying tumorigenesis remain interval(CI)=0.06-0.58; p=0.003). Conclusion: This study unclear. The present study aimed to investigate the role of showed that p16 and MDM2 polymorphisms do not play a → → p16 (540C G and 580C T) and mouse double minute 2 decisive role in tumorigenesis, but some genotypes of these → (MDM2) (SNP309T G) gene polymorphisms in polymorphisms might be associated with follow-up tumorigenesis and characteristics of prolactinoma. Patients characteristics of prolactinoma. and Methods: A total of 74 patients with prolactinoma and 100 age- and gender-matched healthy individuals were Prolactinoma is the most frequent type of functional pituitary enrolled in the study. Serum prolactin levels were measured tumor, with an estimated prevalence of approximately 45 by enzyme-linked immunosorbent assay (ELISA). p16 and cases per 100,000 population in adults (1).
    [Show full text]
  • Multiple Endocrine Neoplasia Type 1 (MEN1)
    Lab Management Guidelines V1.0.2020 Multiple Endocrine Neoplasia Type 1 (MEN1) MOL.TS.285.A v1.0.2020 Introduction Multiple Endocrine Neoplasia Type 1 (MEN1) is addressed by this guideline. Procedures addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedures addressed by this Procedure codes guideline MEN1 Known Familial Mutation Analysis 81403 MEN1 Deletion/Duplication Analysis 81404 MEN1 Full Gene Sequencing 81405 What is Multiple Endocrine Neoplasia Type 1 Definition Multiple Endocrine Neoplasia Type 1 (MEN1) is an autosomal dominant disorder characterized by the development of multiple endocrine and non-endrocrine tumors. Incidence or Prevalence MEN1 has a prevalence of 1/10,000 to 1/100,000 individuals.1 Symptoms The presenting symptom in approximately 90% of individuals with MEN1 is primary hyperparathyroidism (PHPT). Parathyroid tumors cause overproduction of parathyroid hormone which leads to hypercalcemia. The average age of onset is 20-25 years. Parathyroid carcinomas are rare in individuals with MEN1.2,3,4 Pituitary tumors are seen in 30-40% of individuals and are the first clinical manifestation in 10% of familial cases and 25% of simplex cases. Tumors are typically solitary and there is no increased prevalence of pituitary carcinoma in individuals with MEN1.2,5 © 2020 eviCore healthcare. All Rights Reserved. 1 of 8 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Lab Management Guidelines V1.0.2020 Prolactinomas are the most commonly seen pituitary subtype and account for 60% of pituitary adenomas.
    [Show full text]
  • Ganglioneuroblastoma As Vasoactive Intestinal Polypeptide-Secreting10.5005/Jp-Journals-10002-1167 Tumor: Rare Case Report in a Child Case Report
    WJOES Ganglioneuroblastoma as Vasoactive Intestinal Polypeptide-secreting10.5005/jp-journals-10002-1167 Tumor: Rare Case Report in a Child CASE REPORT Ganglioneuroblastoma as Vasoactive Intestinal Polypeptide-secreting Tumor: Rare Case Report in a Child 1Basant Kumar, 2Vijai D Upadhyaya, 3Ram Nawal Rao, 4Sheo Kumar ABSTRACT than 60 cases of pediatric VIP-secreting tumors.3 Most Pathologically elevated vasoactive intestinal polypeptide (VIP) of them are either adrenal pheochromocytoma or mixed plasma levels cause secretory diarrhea with excessive loss of pheochromocytoma-ganglioneuroma tumors. Mason water and electrolyte and is characterized by the typical symp- et al,4 first described the secretory nature of neuroblas- toms of hypokalemia and metabolic acidosis. It rarely occurs toma and vasoactive intestinal peptide (VIP) can be in patients with non-pancreatic disease. Despite the clinical severity, diagnosis of a VIP-secreting tumor is often delayed. produced by the mature neurogenic tumors. We herein We herein present a 14-month-old boy having prolonged present a 14 months old boy having prolonged therapy- therapy-resistant secretory diarrhea, persistent hypokalemia resistant secretory diarrhea, persistent hypokalemia with with tissue diagnosis of ganglioneuroblastoma and raised plasma VIP-levels. tissue diagnosis of ganglioneuroblastoma and briefly review the literature. Keywords: Ganglioneuroblastoma, Secretory diarrhea, VIPoma. CASE REPORT How to cite this article: Kumar B, Upadhyaya VD, Rao RN, Kumar S. Ganglioneuroblastoma as Vasoactive Intestinal A 14-month-old boy, weighing 9 kg with advanced symp- Polypeptide-secreting Tumor: Rare Case Report in a Child. World J Endoc Surg 2015;7(2):47-50. toms of persistent secretory diarrhea, hypokalemia and metabolic acidosis was referred to us with radiological Source of support: Nil (computed tomography) diagnosis of retroperitoneal Conflict of interest: None mass.
    [Show full text]
  • Clinical Radiation Oncology Review
    Clinical Radiation Oncology Review Daniel M. Trifiletti University of Virginia Disclaimer: The following is meant to serve as a brief review of information in preparation for board examinations in Radiation Oncology and allow for an open-access, printable, updatable resource for trainees. Recommendations are briefly summarized, vary by institution, and there may be errors. NCCN guidelines are taken from 2014 and may be out-dated. This should be taken into consideration when reading. 1 Table of Contents 1) Pediatrics 6) Gastrointestinal a) Rhabdomyosarcoma a) Esophageal Cancer b) Ewings Sarcoma b) Gastric Cancer c) Wilms Tumor c) Pancreatic Cancer d) Neuroblastoma d) Hepatocellular Carcinoma e) Retinoblastoma e) Colorectal cancer f) Medulloblastoma f) Anal Cancer g) Epndymoma h) Germ cell, Non-Germ cell tumors, Pineal tumors 7) Genitourinary i) Craniopharyngioma a) Prostate Cancer j) Brainstem Glioma i) Low Risk Prostate Cancer & Brachytherapy ii) Intermediate/High Risk Prostate Cancer 2) Central Nervous System iii) Adjuvant/Salvage & Metastatic Prostate Cancer a) Low Grade Glioma b) Bladder Cancer b) High Grade Glioma c) Renal Cell Cancer c) Primary CNS lymphoma d) Urethral Cancer d) Meningioma e) Testicular Cancer e) Pituitary Tumor f) Penile Cancer 3) Head and Neck 8) Gynecologic a) Ocular Melanoma a) Cervical Cancer b) Nasopharyngeal Cancer b) Endometrial Cancer c) Paranasal Sinus Cancer c) Uterine Sarcoma d) Oral Cavity Cancer d) Vulvar Cancer e) Oropharyngeal Cancer e) Vaginal Cancer f) Salivary Gland Cancer f) Ovarian Cancer & Fallopian
    [Show full text]
  • Neuroendocrine Tumors of the Pancreas (Including Insulinoma, Gastrinoma, Glucogacoma, Vipoma, Somatostatinoma)
    Neuroendocrine tumors of the pancreas (including insulinoma, gastrinoma, glucogacoma, VIPoma, somatostatinoma) Neuroendocrine pancreatic tumors (pancreatic NETs or pNETs) account for about 3% of all primary pancreatic tumors. They develop in neuroendocrine cells called islet cells. Neuroendocrine tumors of the pancreas may be nonfunctional (not producing hormones) or functional (producing hormones). Most pNETs do not produce hormones and, as a result, these tumors are diagnosed incidentally or after their growth causes symptoms such as abdominal pain, jaundice or liver metastasis. pNETs that produce hormones are named according to the type of hormone they produce and / or clinical manifestation: Insulinoma - An endocrine tumor originating from pancreatic beta cells that secrete insulin. Increased insulin levels in the blood cause low glucose levels in blood (hypoglycemia) with symptoms that may include sweating, palpitations, tremor, paleness, and later unconsciousness if treatment is delayed. These are usually benign and tend to be small and difficult to localize. Gastrinoma - a tumor that secretes a hormone called gastrin, which causes excess of acid secretion in the stomach. As a result, severe ulcerative disease and diarrhea may develop. Most gastrinomas develop in parts of the digestive tract that includes the duodenum and the pancreas, called "gastrinoma triangle". These tumors have the potential to be malignant. Glucagonoma is a rare tumor that secretes the hormone glucagon, which may cause a typical skin rash called migratory necrolytic erythema, elevated glucose levels, weight loss, diarrhea and thrombotic events. VIPoma - a tumor that secretes Vasoactive peptide (VIP) hormone causing severe diarrhea. The diagnosis is made by finding a pancreatic neuroendocrine tumor with elevated VIP hormone in the blood and typical clinical symptoms.
    [Show full text]
  • Multiple Endocrine Neoplasia Type 1 (MEN1)
    Lab Management Guidelines v2.0.2019 Multiple Endocrine Neoplasia Type 1 (MEN1) MOL.TS.285.A v2.0.2019 Introduction Multiple Endocrine Neoplasia Type 1 (MEN1) is addressed by this guideline. Procedures addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedures addressed by this Procedure codes guideline MEN1 Known Familial Mutation Analysis 81403 MEN1 Deletion/Duplication Analysis 81404 MEN1 Full Gene Sequencing 81405 What is Multiple Endocrine Neoplasia Type 1 Definition Multiple Endocrine Neoplasia Type 1 (MEN1) is an inherited form of tumor predisposition characterized by multiple tumors of the endocrine system. Incidence or Prevalence MEN1 has a prevalence of 1/10,000 to 1/100,000 individuals.1 Symptoms The presenting symptom in 90% of individuals with MEN1 is primary hyperparathyroidism (PHPT). Parathyroid tumors cause overproduction of parathyroid hormone which leads to hypercalcemia. The average age of onset is 20-25 years. Parathyroid carcinomas are rare in individuals with MEN1.2,3,4 Pituitary tumors are seen in 30-40% of individuals and are the first clinical manifestation in 10% of familial cases and 25% of simplex cases. Tumors are typically solitary and there is no increased prevalence of pituitary carcinoma in individuals with MEN1.2,5 © eviCore healthcare. All Rights Reserved. 1 of 9 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Lab Management Guidelines v2.0.2019 Prolactinomas are the most commonly seen pituitary subtype and account for 60% of pituitary adenomas.
    [Show full text]
  • Neoplastic Metastases to the Endocrine Glands
    27 1 Endocrine-Related A Angelousi et al. Metastases to endocrine 27:1 R1–R20 Cancer organs REVIEW Neoplastic metastases to the endocrine glands Anna Angelousi1, Krystallenia I Alexandraki2, George Kyriakopoulos3, Marina Tsoli2, Dimitrios Thomas2, Gregory Kaltsas2 and Ashley Grossman4,5,6 1Endocrine Unit, 1st Department of Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece 2Endocrine Unit, 1st Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece 3Department of Pathology, General Hospital ‘Evangelismos’, Αthens, Greece 4Department of Endocrinology, OCDEM, University of Oxford, Oxford, UK 5Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK 6Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK Correspondence should be addressed to A Angelousi: [email protected] Abstract Endocrine organs are metastatic targets for several primary cancers, either through Key Words direct extension from nearby tumour cells or dissemination via the venous, arterial and f glands lymphatic routes. Although any endocrine tissue can be affected, most clinically relevant f cancer metastases involve the pituitary and adrenal glands with the commonest manifestations f metastases being diabetes insipidus and adrenal insufficiency respectively. The most common f pituitary primary tumours metastasing to the adrenals include melanomas, breast and lung f adrenal carcinomas, which may lead to adrenal insufficiency in the presence of bilateral adrenal f thyroid involvement. Breast and lung cancers are the most common primaries metastasing to f ovaries the pituitary, leading to pituitary dysfunction in approximately 30% of cases. The thyroid gland can be affected by renal, colorectal, lung and breast carcinomas, and melanomas, but has rarely been associated with thyroid dysfunction.
    [Show full text]
  • Rising Incidence of Neuroendocrine Tumors
    Rising Incidence of Neuroendocrine Tumors Dasari V, Yao J, et al. JAMA Oncology 2017 S L I D E 1 Overview Pancreatic Neuroendocrine Tumors • Tumors which arise from endocrine cells of the pancreas • 5.6 cases per million – 3% of pancreatic tumors • Median age at diagnosis 60 years • More indolent course compared to adenocarcinoma – 10-year overall survival 40% • Usually sporadic but can be associated with hereditary syndromes – Core genetic pathways altered in sporadic cases • DNA damage repair (MUTYH) Chromatin remodeling (MEN1) • Telomere maintenance (MEN1, DAXX, ATRX) mTOR signaling – Hereditary: 17% of patients with germline mutation Li X, Wang C, et al. Cancer Med 2018 Scarpa A, Grimond S, et al. NatureS L I2017 D E 2 Pathology Classification European American Joint World Health Organization Neuroendocrine Committee on Cancer (WHO) Tumor Society (AJCC) (ENETS) Grade Ki-67 Mitotic rt TNM TNM T1: limit to pancreas, <2 cm T1: limit to pancreas, ≦2 cm T2: limit to pancreas, 2-4 cm T2: >limit to pancreas, 2 cm T3: limit to pancreas, >4 cm, T3: beyond pancreas, no celiac or Low ≤2% <2 invades duodenum, bile duct SMA T4: beyond pancreas, invasion involvement adjacent organs or vessels T4: involves celiac or SMA N0: node negative No: node negative Intermed 3-20% 2-20 N1: node positive N1: node positive M0: no metastases M0: no metastases High >20% >20 M1: metastases M1: metastases S L I D E 3 Classification Based on Functionality • Nonfunctioning tumors – No clinical symptoms (can still produce hormone) – Accounts for 40% of tumors – 60-85%
    [Show full text]
  • Pituitary Adenomas: from Diagnosis to Therapeutics
    biomedicines Review Pituitary Adenomas: From Diagnosis to Therapeutics Samridhi Banskota 1 and David C. Adamson 1,2,3,* 1 School of Medicine, Emory University, Atlanta, GA 30322, USA; [email protected] 2 Department of Neurosurgery, Emory University, Atlanta, GA 30322, USA 3 Neurosurgery, Atlanta VA Healthcare System, Decatur, GA 30322, USA * Correspondence: [email protected] Abstract: Pituitary adenomas are tumors that arise in the anterior pituitary gland. They are the third most common cause of central nervous system (CNS) tumors among adults. Most adenomas are benign and exert their effect via excess hormone secretion or mass effect. Clinical presentation of pituitary adenoma varies based on their size and hormone secreted. Here, we review some of the most common types of pituitary adenomas, their clinical presentation, and current diagnostic and therapeutic strategies. Keywords: pituitary adenoma; prolactinoma; acromegaly; Cushing’s; transsphenoidal; CNS tumor 1. Introduction The pituitary gland is located at the base of the brain, coming off the inferior hy- pothalamus, and weighs no more than half a gram. The pituitary gland is often referred to as the “master gland” and is the most important endocrine gland in the body because it regulates vital hormone secretion [1]. These hormones are responsible for vital bodily Citation: Banskota, S.; Adamson, functions, such as growth, blood pressure, reproduction, and metabolism [2]. Anatomically, D.C. Pituitary Adenomas: From the pituitary gland is divided into three lobes: anterior, intermediate, and posterior. The Diagnosis to Therapeutics. anterior lobe is composed of several endocrine cells, such as lactotropes, somatotropes, and Biomedicines 2021, 9, 494. https: corticotropes, which synthesize and secrete specific hormones.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]